使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day and thank you for standing by. Welcome to Indivior Pharmaceuticals, Inc.'s fourth-quarter and full-year 2025 results conference call and webcast. (Operator Instructions) Please note that today's conference is being recorded. I would now like to hand the conference over to Jason Thompson, your host for today's call. Please go ahead.
大家好,感謝您的耐心等待。歡迎參加Indivior Pharmaceuticals, Inc. 2025年第四季及全年業績電話會議及網路直播。 (操作說明)請注意,本次會議正在錄音。現在我將會議交給今天的主持人Jason Thompson先生。請開始。
Jason Thompson - Head - Investor Relations
Jason Thompson - Head - Investor Relations
Thank you, and good morning, everyone. I am joined today by Joe Ciaffoni, Chief Executive Officer; Patrick Barry, Chief Commercial Officer; and Ryan Preblick, Chief Financial Officer. We're also joined by Christian Heidbreder, our Chief Scientific Officer.
謝謝大家,早安。今天與我一同出席的有執行長喬·恰福尼、首席商務官帕特里克·巴里、首席財務官瑞安·普雷布里克,以及首席科學官克里斯蒂安·海德布雷德。
Before we begin, I need to remind everyone that on today's call, we may make forward-looking statements that are subject to risks and uncertainties, and that actual results may differ materially. We list the factors that may cause our results to be materially different here on slide 2 of this presentation. We also may refer to non-GAAP measures, the reconciliations for which may also be found in the appendix to this presentation that is now posted on our website at indivior.com. I'll now turn the call over to Joe Ciaffoni, our CEO.
在會議開始之前,我需要提醒各位,在今天的電話會議中,我們可能會做出一些前瞻性陳述,這些陳述受風險和不確定性因素的影響,實際結果可能與預期有重大差異。我們已在本簡報的第二頁列出了可能導致實際結果與預期有重大差異的因素。此外,我們也可能提及非GAAP財務指標,這些指標的調整表也已發佈在本簡報的附錄中,該附錄現已上傳至我們的網站indivior.com。現在,我將把電話會議交給我們的執行長Joe Ciaffoni先生。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Thanks, Jason, good morning and thank you for joining us on today's call to review our Q4 and full-year 2025 results. I will begin with an overview of our business performance in 2025 and summarize our progress against the Indivior Action Agenda. Pat will then provide a commercial update and discuss our priorities for SUBLOCADE. Finally, Ryan will review our financial performance, 2026 guidance, and then detail our capital deployment strategy. 2025 was a transition year for the company.
謝謝Jason,早安,謝謝您參加今天的電話會議,共同回顧我們2025年第四季及全年業績。我將首先概述我們2025年的業務表現,並總結我們在Indivior行動計劃方面的進展。接下來,Pat將帶來最新的商業動態,並討論SUBLOCADE的優先事項。最後,Ryan將回顧我們的財務表現、2026年績效指引,並詳細介紹我們的資本部署策略。 2025年是公司轉型的一年。
Last July, we rolled out the Indivior Action Agenda to maximize the potential of our business, make a positive difference in the lives of people living with opioid use disorder, and to create value for our shareholders. We've made significant progress, including successfully completing Phase 1, generate momentum, and delivering against our financial commitments for 2025.
去年七月,我們推出了“Indivior行動計劃”,旨在最大限度地發揮公司潛力,為阿片類藥物使用障礙患者的生活帶來積極改變,並為股東創造價值。我們已取得顯著進展,包括成功完成第一階段,保持發展勢頭,並兌現了2025年的財務承諾。
Specifically, we improved our commercial execution and generated momentum for SUBLOCADE, delivering record net revenue in 2025 of $856 million, a 13% increase versus 2024, and total net revenue of $1.24 billion, representing a 4% increase compared to the prior year. We took several actions to simplify our organization and establish Indivior's go-forward operating model. Operating expenses will not exceed $450 million in 2026. We grew adjusted EBITDA 20% year-over-year to $428 million in 2025, along with notable margin improvement.
具體而言,我們提升了商業執行力,並為SUBLOCADE業務注入了強勁動力,使其在2025年實現了創紀錄的8.56億美元淨收入,較2024年增長13%;總淨收入達到12.4億美元,較上年增長4%。我們採取了多項措施簡化組織架構,並建立了Indivior未來的營運模式。 2026年營運支出將不超過4.5億美元。 2025年,我們調整後的EBITDA年增20%至4.28億美元,同時利潤率也顯著提升。
We launched a new direct-to-consumer campaign, Move Forward in Recovery, on October 1, 2025, to drive awareness of SUBLOCADE among people living with opioid use disorder. Although early, we are encouraged by the engagement we are seeing and all key leading indicators are trending ahead of expectations.
我們於2025年10月1日啟動了一項名為「攜手康復」(Move Forward in Recovery)的全新面向消費者的宣傳活動,旨在提高阿片類藥物使用障礙患者對SUBLOCADE的認知度。儘管目前尚處於初期階段,但我們對目前的參與感到鼓舞,所有關鍵指標都超出預期。
Finally, we strengthened our financial profile, including paying the outstanding $295 million obligation related to the legacy DOJ matter, thereby eliminating a significant future liability for our company. I want to thank the Indivior team for their contributions to our progress against the Indivior Action Agenda and their unwavering dedication to people living with opioid use disorder in the communities we serve.
最後,我們增強了財務實力,包括償還了與司法部遺留案件相關的2.95億美元未償債務,消除了公司未來可能面臨的重大債務。我要感謝Indivior團隊為我們推進Indivior行動議程所做的貢獻,以及他們對我們所服務社區中阿片類藥物使用障礙患者的堅定奉獻。
Our strong financial performance and the momentum we generated in 2025 position us to accelerate in 2026. Our confidence in the business is reinforced by our new $400 million share repurchase program authorized by our board that we announced this morning.
我們強勁的財務表現和2025年取得的良好勢頭,使我們能夠在2026年加速發展。今天上午,我們宣布了一項由董事會批准的4億美元股票回購計劃,這進一步增強了我們對業務的信心。
With Phase 1 of the Indivior Action Agenda completed and our go-forward operating model firmly established, we are now executing on Phase 2 of the Indivior Action Agenda, Accelerate. During this phase, we expect to accelerate SUBLOCADE dispense unit growth and net revenue throughout 2026 and immediately grow adjusted EBITDA and cash flow at a faster rate.
隨著Indivior行動計劃第一階段的完成以及我們未來營運模式的穩固確立,我們目前正在執行Indivior行動計劃第二階段—加速發展。在此階段,我們預計在2026年全年加速SUBLOCADE分銷單元的成長和淨收入的提升,並立即加快調整後EBITDA和現金流的成長速度。
SUBLOCADE is the first and number one prescribed long-acting injectable for the treatment of moderate to severe opioid use disorder. It is the only monthly long-acting injectable with an indication for rapid initiation and has been prescribed to over 475,000 people. We believe that SUBLOCADE is a durable growth driver with 12 Orange Book-listed patents that range from 2031 to 2038. We are committed to investing at sustained levels to maximize the potential of SUBLOCADE and grow the long-acting injectable market.
SUBLOCADE是第一個也是處方量排名第一的用於治療中重度鴉片類藥物使用障礙的長效注射劑。它是唯一一款每月注射一次且可快速啟動治療的長效注射劑,已為超過47.5萬名患者開立處方。我們相信,SUBLOCADE擁有12項列入橙皮書的專利,有效期從2031年到2038年,因此具有持久的成長潛力。我們將持續加大投資,以最大限度地發揮SUBLOCADE的潛力,並推動長效注射劑市場的發展。
Although we are making progress, we believe long-acting injectables remain underutilized. We expect our laser focus on improving commercial execution, our sustained investments in patient education and activation, and efforts to advance state and federal policies that support greater treatment access will drive the acceleration of SUBLOCADE.
儘管我們取得了一些進展,但我們認為長效注射劑仍未充分利用。我們期望透過以下措施加速推進SUBLOCADE計畫:專注於提升商業執行力;持續投入病患教育和推廣;以及努力推動州和聯邦政策的製定,以擴大治療的可及性。
I am encouraged by the trends we are seeing across all key metrics thus far in the Q1. In 2026, we expect to deliver SUBLOCADE dispense unit growth in the mid-teens, an acceleration compared to the 7% dispense unit growth we achieved in 2025. This will result in SUBLOCADE net revenue growth of 8% at the midpoint of our guidance range.
我對第一季迄今為止所有關鍵指標的趨勢感到鼓舞。我們預計,2026年SUBLOCADE的銷售單位成長率將達到15%左右,較2025年7%的成長率加速。這將使SUBLOCADE的淨收入成長率達到我們預期範圍的中位數8%。
The leverage generated by our go-forward operating model will immediately accelerate adjusted EBITDA and cash flow at a faster rate. We expect to generate 30% adjusted EBITDA growth in 2026, representing a 13 percentage point improvement in our adjusted EBITDA margin compared to 2025, and we expect to generate approximately $300 million in cash flow from operations. Our increased cash flow and strong financial position will enable us to strategically deploy capital to create value for our shareholders.
我們未來營運模式帶來的槓桿效應將立即加速調整後 EBITDA 和現金流的成長。我們預計 2026 年調整後 EBITDA 將成長 30%,較 2025 年調整後 EBITDA 利潤率提高 13 個百分點,並預計營運現金流約為 3 億美元。我們不斷增長的現金流和穩健的財務狀況將使我們能夠策略性地部署資本,為股東創造價值。
Our capital deployment priorities are threefold: manage our debt, opportunistically deploy our newly authorized $400 million share repurchase program, and evaluate potential business development opportunities to acquire the next commercial stage growth drivers as we earn our way to Phase 3 of the Indivior Action Agenda breakout.
我們的資本部署重點有三方面:管理債務、抓住機會部署新批准的 4 億美元股票回購計劃,以及評估潛在的業務發展機會,以獲得下一個商業階段的成長驅動因素,從而為進入 Indivior 行動議程第三階段做好準備。
We are encouraged by, but not satisfied with, the progress we made in 2025. The actions we took and the foundation we established strongly position us to achieve our financial and operational objectives in Phase 2, accelerate, in 2026.
我們對2025年的進展感到鼓舞,但並不滿足。我們採取的行動和奠定的基礎使我們能夠在2026年第二階段加速實現財務和營運目標。
I'll now turn the call over to Pat.
現在我將把電話交給帕特。
Patrick Barry - Chief Commercial Officer
Patrick Barry - Chief Commercial Officer
Thanks, Joe, and good morning, everyone. As part of Phase 1 of the Indivior Action Agenda, generate momentum, we have been focused on improving commercial execution for SUBLOCADE. Our commercial team is dedicated to helping people living with OUD, and they have a strong belief in SUBLOCADE as the first and number one prescribed long-acting injectable in the category.
謝謝喬,大家早安。作為Indivior行動計畫第一階段(旨在推動市場發展)的一部分,我們一直致力於提升SUBLOCADE的商業執行力。我們的商業團隊致力於協助阿片類藥物使用障礙(OUD)患者,他們堅信SUBLOCADE是該品類中首個也是排名第一的處方長效注射劑。
We have made progress on our commercial execution initiatives, which are reflected in our Q4 and full year results. In the Q4, we delivered strong dispense unit growth of 12% versus the prior year and 6% versus the Q3.
我們在商業執行方面取得了進展,這體現在第四季度和全年業績中。第四季度,我們的銷售單位數量較去年同期成長12%,較上季成長6%,表現強勁。
New patient starts in the Q4 were up 25% year-over-year, and over the course of the last 10 weeks of the year, weekly new patient starts achieved all-time highs on three separate occasions. Total category share of LAIs and new patient share in the US for SUBLOCADE continued to stabilize in the mid-70s. We exited 2025 with a record number of active SUBLOCADE prescribers, including those treating five or more patients.
第四季新患者起始治療量較去年同期成長25%,在年末最後10週內,每週新患者起始治療量三次創下歷史新高。長效注射劑(LAI)在美國的總市場份額以及SUBLOCADE的新患者市佔率持續穩定在70%左右。截至2025年底,SUBLOCADE的活躍處方醫生數量創歷史新高,其中包括治療五名或以上患者的醫生。
In the Q4, both total active SUBLOCADE prescribers and prescribers treating five or more patients grew 14% year-over-year and approximately 6% sequentially. We believe this progress represents a combination of the fundamental strengths of SUBLOCADE, along with our improving commercial execution. We are encouraged by the momentum we generated exiting 2025 and are well positioned to accelerate in 2026.
第四季度,SUBLOCADE 的活躍處方醫生總數以及治療五名或以上患者的處方醫生數量均同比增長 14%,環比增長約 6%。我們認為,這項進展得益於 SUBLOCADE 本身的強大優勢以及我們不斷提升的商業執行力。我們對 2025 年底取得的良好勢頭感到鼓舞,並已做好充分準備,在 2026 年加速發展。
We remain focused on continuous improvement in commercial execution to accelerate SUBLOCADE prescribing volume for the benefit of people living with OUD. Our efforts are centered on driving excellence and field force messaging, improving commercial channel productivity, growing patient activation and new starts, and unlocking treatment access through proactive engagement with policy leaders. We have seen improvements across each of these areas.
我們始終致力於持續改善商業執行,以加快SUBLOCADE的處方量,造福鴉片類藥物使用障礙患者。我們的工作重點在於提升卓越營運和銷售團隊訊息傳遞,提高商業管道效率,增強患者激活率和新開處方量,並透過與政策制定者積極溝通,擴大治療覆蓋範圍。我們在這些方面均已取得顯著成效。
Our field force messaging acumen that is focused on SUBLOCADE's differentiated label is driving growth in the number of physicians utilizing the accelerated second dose. Approximately 7% of new patients received the accelerated second dose, and 17% of active HCPs prescribed a second dose in line with the expanded SUBLOCADE label.
我們銷售團隊針對SUBLOCADE差異化適應症的精準宣傳,正推動越來越多的醫師採用加速第二劑給藥方案。約7%的新患者接受了加速第二劑給藥,17%的活躍醫護人員根據SUBLOCADE擴展適應症開立了第二劑處方。
On commercial dispense yield productivity, we remain in the early stages of improving yields towards our non-commercial channel average of approximately 80%. We are seeing steady progress with our targeted commercial specialty pharmacies and expect steady yield improvement as we move through 2026.
在商業通路藥品分銷效率方面,我們仍處於提升分銷效率的初期階段,目標是達到非商業通路平均約 80%。我們與目標商業專科藥局的合作正在穩步推進,預計到 2026 年,分銷效率將持續提升。
In addition to these commercial improvement initiatives, we are investing to expand patient awareness and engagement. Last October, we launched our direct-to-consumer campaign, Move Forward in Recovery, which is designed to emotionally and authentically connect with people living with OUD and drive awareness of SUBLOCADE as a treatment option for those struggling with moderate to severe opioid addiction.
除了這些商業改進措施之外,我們也正在投資提升患者的認知度和參與度。去年十月,我們啟動了面向消費者的「康復之路」(Move Forward in Recovery)活動,旨在與阿片類藥物使用障礙(OUD)患者建立情感上的真實聯繫,並提高人們對SUBLOCADE作為中重度阿片類藥物成癮治療方案的認知度。
Recall, this campaign has an omni-channel approach, including national television, digital and social media, and in-office point-of-care materials, along with a newly designed SUBLOCADE patient website. We are seeing early indicators of success following the launch of the campaign. For example, prompted awareness among patients has increased versus the Q1 of 2025.
請注意,本次宣傳活動採用全通路策略,涵蓋全國電視、數位媒體和社群媒體、診室內的宣傳資料,以及全新設計的SUBLOCADE病患網站。活動啟動後,我們已看到初步的成功跡象。例如,與2025年第一季相比,患者的認知度有所提高。
Branded online search volume increased 60% in the Q4 compared to the months immediately prior to the launch of the campaign, driving high-quality engagement on the SUBLOCADE website, including a 70% increase in usage of the Find a SUBLOCADE Treatment Provider tool.
與該活動推出前的幾個月相比,第四季度品牌線上搜尋量成長了 60%,推動了 SUBLOCADE 網站上的高品質互動,其中「尋找 SUBLOCADE 療程提供者」工具的使用量增加了 70%。
We also saw an average of around 1,400 new CRM enrollments per month in the Q4, versus around 60 per month immediately prior to the new campaign, reflecting meaningful and tenure-driven patient action. We are also actively pursuing opportunities to expand patient access through our proactive public policy initiatives.
第四季度,我們平均每月新增約 1400 例 CRM 註冊,而新活動開展前每月新增註冊量約為 60 例,這反映出患者採取了切實有效的行動,且這些行動與患者的長期用藥密切相關。此外,我們也積極尋求機會,透過我們主動的公共政策措施來擴大病患的就醫管道。
For example, in several states, long-acting injectables are only available under a medical benefit. This creates logistical complexity, upfront cost, and administrative burden for providers. Expanding coverage under a pharmacy benefit would reduce these barriers, lower financial risk, and improve provider adoption.
例如,在某些州,長效注射劑只能透過醫療保險報銷。這給醫療服務提供者帶來了後勤方面的複雜性、前期成本和行政負擔。如果將長效注射劑納入藥局福利的覆蓋範圍,就能減少這些障礙,降低財務風險,並提高醫療服務提供者的接受度。
In parallel, we are engaging on bundled payment structures to help ensure that long-acting injectables are appropriately recognized, whether through potential carve-outs or a more accurate reflection in overall payment levels. This would strengthen the financial viability of treating people with OUD.
同時,我們正在積極探索打包支付模式,以確保長效注射劑得到應有的認可,無論是透過潛在的費用減免,還是在整體支付水平上更準確地反映其價值。這將有助於提高阿片類藥物使用障礙(OUD)患者治療的經濟可行性。
Taken together, our improving commercial execution, patient activation efforts, and policy initiatives are laying the foundation for SUBLOCADE acceleration and give us confidence in our ability to deliver mid-teens dispense unit growth in 2026.
綜合來看,我們不斷改進的商業執行、患者活化工作和政策舉措正在為 SUBLOCADE 的加速發展奠定基礎,並使我們有信心在 2026 年實現十幾個百分點的配藥量增長。
I will now turn the call over to Ryan.
現在我將把通話轉給瑞恩。
Ryan Preblick - Chief Financial Officer
Ryan Preblick - Chief Financial Officer
Thanks, Pat. Good morning. First, I'll highlight our Q4 and full year financial performance, followed by a review of our 2026 guidance, and close on our capital deployment strategy. We delivered on our financial commitments in 2025. We grew total SUBLOCADE net revenue by 13% and adjusted EBITDA by 20% year-over-year.
謝謝,帕特。早安.首先,我將重點介紹我們第四季和全年的財務業績,然後回顧我們2026年的業績指引,最後談談我們的資本部署策略。我們實現了2025年的財務承諾。 SUBLOCADE的總淨收入年增13%,調整後EBITDA年增20%。
We simplified the organization while strengthening our financial profile. We are well-positioned to execute on Phase 2 of the Indivior Action Agenda, Accelerate. Looking at our results in more detail, starting with the top line. Total net revenue of $358 million for the Q4 and approximately $1.24 billion for the full year increased 20% and 4%, respectively, versus the prior year periods. The increase for both periods was driven by strong SUBLOCADE net revenue growth.
我們簡化了組織架構,同時增強了財務實力。我們已做好充分準備,推進Indivior行動計畫第二階段-加速發展。接下來,我們將更詳細地分析業績,先來看看營收。第四季淨營收達3.58億美元,全年淨營收約12.4億美元,分別較上年同期成長20%及4%。這兩個季度的營收成長均主要得益於SUBLOCADE業務的強勁成長。
Total SUBLOCADE net revenue of $252 million for the quarter and $856 million for the year increased 30% and 13%, respectively, versus the prior year periods. For the Q4, SUBLOCADE dispense volume grew 12% year-over-year and 6% versus the prior quarter. For the full year, SUBLOCADE dispense volume grew 7%. Gross and net benefits also contributed to the increase in SUBLOCADE net revenue for both periods.
本季SUBLOCADE淨收入總計2.52億美元,全年淨收入總計8.56億美元,分別較上年同期成長30%及13%。第四季SUBLOCADE的銷售量年增12%,季增6%。全年SUBLOCADE的銷售量成長7%。毛利和淨收益也對兩個時期SUBLOCADE淨收入的成長做出了貢獻。
The Q4 included a gross and net benefit of approximately $19 million and $10 million due to an increase in trade inventory of approximately two days. The full year included a gross and net benefit of approximately $49 million.
第四季毛收益和淨收益分別約為1900萬美元和1000萬美元,主要原因是貿易庫存增加了約兩天。全年毛收益和淨收益約4900萬美元。
Turning to SUBOXONE Film net revenue, in the Q4 and full year, we benefited from continued generic price stability in the US. Q4 SUBOXONE Film net revenue included a gross and net benefit of $23 million, and the full year included a gross and net benefit of $55 million.
就舒巴克松薄膜劑的淨收入而言,第四季和全年均受益於美國仿製藥價格的持續穩定。第四季舒巴克松薄膜劑的淨收入包括2,300萬美元的毛利和淨收益,全年毛利和淨收益為5,500萬美元。
Total non-GAAP operating expenses were $164 million for the Q4 and $622 million for the full year, down 8% and 5%, respectively, versus the same year-ago periods. Non-GAAP SG&A expenses were $148 million for the Q4 and $545 million for the full year, down 2% and 1%, respectively, versus the prior-year periods. The decreases in both periods were driven by reductions in headcount and footprint consolidations across the organization, partially offset by an increased selling and marketing investments behind US SUBLOCADE.
第四季非GAAP營運總支出為1.64億美元,全年為6.22億美元,分別較上年同期下降8%和5%。第四季非GAAP銷售、管理及行政費用為1.48億美元,全年為5.45億美元,分別較上年同期下降2%及1%。這兩個時期支出的下降主要歸因於公司內部人員精簡和業務整合,但部分被美國子業務部門銷售和行銷投入的增加所抵消。
Non-GAAP R&D expenses were $17 million for the Q4 and $80 million for the full year, down 36% and 22% year-over-year, respectively. The decreases in both periods were driven by the reprioritization of pipeline activities and the restructuring of the R&D and medical affairs organizations.
第四季非GAAP研發費用為1,700萬美元,全年為8,000萬美元,年減36%和22%。這兩個時期研發費用的下降主要歸因於研發管線活動的重新調整以及研發和醫學事務部門的重組。
Charges related to the simplification actions we took as part of Phase 1 of the Indivior Action Agenda were $55 million in the Q4 and $120 million in 2025. These charges include severance costs, write-offs for leases, inventory, equipment, and intangibles, as well as other termination payments and consulting costs.
作為 Indivior 行動計畫第一階段的一部分,我們採取的簡化措施相關的費用在第四季度為 5,500 萬美元,2025 年為 1.2 億美元。這些費用包括遣散費、租賃、庫存、設備和無形資產的註銷,以及其他終止付款和諮詢費用。
The related cash costs were approximately $28 million in 2025. Looking at the bottom line, we generated record adjusted EBITDA for the Q4 and full year. Adjusted EBITDA for the Q4 increased 91% year-over-year to $142 million. For the full year, Adjusted EBITDA grew 20% to $428 million, with margin improvement of 500 basis points.
2025年相關現金成本約2,800萬美元。從獲利情況來看,我們第四季和全年的調整後EBITDA均創歷史新高。第四季調整後EBITDA年增91%至1.42億美元。全年調整後EBITDA成長20%至4.28億美元,利潤率提升500個基點。
We are reaffirming our 2026 financial guidance, which reflects the go-forward operating model we established by completing Phase 1 of the Indivior Action Agenda. We expect total net revenue in the range of $1.125 billion-$1.195 billion. The modest decline in net revenue at the midpoint versus 2025 is mainly due to the expected US SUBOXONE Film pressure, lower net revenue from the rest of the world due to the optimization we conducted last year, and the continued runoff of PERSERIS.
我們重申2026年財務預期,該預期反映了我們透過完成Indivior行動計畫第一階段而建立的未來營運模式。我們預計總淨收入將在11.25億美元至11.95億美元之間。與2025年相比,淨收入中位數略有下降,主要原因是預計美國市場對SUBOXONE薄膜劑的需求壓力、去年優化後全球其他地區淨收入的減少,以及PERSERIS的持續減產。
We expect total SUBLOCADE net revenue in the range of $905 million-$945 million, representing growth of 8% at the midpoint versus 2025. We expect to accelerate US SUBLOCADE dispense unit growth to the mid-teens in 2026 from 7% in 2025.
我們預計 SUBLOCADE 總淨收入將在 9.05 億美元至 9.45 億美元之間,以中間值計算,較 2025 年成長 8%。我們預計 SUBLOCADE 美國分銷單位的成長速度將從 2025 年的 7% 加快至 2026 年的 15% 左右。
By leveraging our new operating model that we've established as part of Phase 1 of the Indivior Action Agenda, Generate Momentum, we expect non-GAAP operating expenses in the range of $430 million-$450 million. We expect adjusted EBITDA in the range of $535 million-$575 million, which at the midpoint, is an increase of 30% versus 2025 and would represent 13 percentage points of margin expansion to 48%.
透過運用我們作為「Indivior行動計畫」第一階段「加速發展」的一部分而建立的全新營運模式,我們預計非GAAP營運費用將在4.3億美元至4.5億美元之間。我們預期調整後EBITDA將在5.35億美元至5.75億美元之間,取中間值,較2025年成長30%,利潤率將提升13個百分點至48%。
With the successful completion of Phase 1 of the Indivior Action Agenda, Generate Momentum, we have strengthened our financial profile and will continue to improve upon this foundation as we execute on Phase 2, Accelerate. We ended the year with gross cash and investments of $222 million, even after concluding the legacy DOJ matter by paying the outstanding obligation of $295 million.
隨著Indivior行動計畫第一階段「積蓄動力」的成功完成,我們的財務狀況得到鞏固,並將繼續在此基礎上,推進第二階段「加速發展」。即使在支付了2.95億美元的未償債務,結束了與美國司法部遺留的案件之後,我們年底的現金及投資總額仍達到2.22億美元。
Excluding the impacts from settlement and restructuring payments, underlying cash flow from operations was over $200 million in 2025. We ended the year with net leverage below one time. In 2026, we expect to generate over $300 million in cash flow from operations, enabling us to strategically deploy capital to create long-term value for our shareholders.
剔除和解及重組付款的影響,2025年公司經營活動產生的現金流量超過2億美元。年底淨槓桿率低於1倍。預計2026年,公司經營活動產生的現金流將超過3億美元,因此能夠策略性地部署資本,為股東創造長期價值。
Our capital deployment priorities include managing our debt, returning value to shareholders through opportunistic share repurchases, and evaluating business development opportunities as we earn our way to Phase 3 of the Indivior Action Agenda breakout.
我們的資本部署重點包括管理債務、透過機會性股票回購為股東創造價值,以及在我們努力進入 Indivior 行動議程第三階段的過程中評估業務發展機會。
Today, we announced that our board authorized a new share repurchase program of up to $400 million, with a term up to 18 months. We plan to utilize this program opportunistically to return value to our shareholders.
今天,我們宣布董事會已批准一項新的股票回購計劃,金額最高可達4億美元,期限最長為18個月。我們計劃根據市場狀況靈活運用該計劃,為股東創造價值。
As we earn our way to Phase 3 breakout, we will evaluate business development opportunities specifically focused on commercial stage assets that have the potential to enhance and diversify our growth profile. Our financial strength provides us with capital deployment optionality. We are committed to taking a disciplined approach.
隨著我們逐步邁向第三階段突破,我們將評估業務發展機會,並專注於那些具有提升和多元化我們成長潛力的商業化階段資產。我們雄厚的財務實力為我們提供了資本部署的選擇權。我們致力於採取嚴謹的策略。
I'll now turn the call back over to Joe for concluding remarks.
現在我將把電話交還給喬,請他做總結發言。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Thanks, Ryan. 2025 was a year of significant progress against the Indivior Action Agenda. We sharpened our focus on our highest growth opportunity, US SUBLOCADE, established our go-forward operating model, and strengthened our financial profile. We are now executing Phase 2 of the Indivior Action Agenda, accelerate, in which we expect to accelerate SUBLOCADE throughout 2026 and immediately accelerate adjusted EBITDA and cash flow at a faster rate.
謝謝瑞恩。 2025年是我們在推進Indivior行動計畫方面取得顯著進展的一年。我們更專注於成長潛力最大的專案—美國SUBLOCADE,建立了未來的營運模式,並增強了財務實力。目前,我們正在執行Indivior行動計畫的第二階段-加速階段,預計2026年加速SUBLOCADE的發展,並立即加快調整後EBITDA和現金流的成長速度。
With the establishment of our capital deployment strategy, we are focused on creating long-term value for our shareholders as we work towards becoming a leading, diversified specialty pharmaceutical company, committed to making a positive difference in the lives of people through the commercialization of differentiated medicines.
隨著我們資本部署策略的建立,我們致力於為股東創造長期價值,並努力成為一家領先的多元化專業製藥公司,致力於透過差異化藥物的商業化為人們的生活帶來積極改變。
We will now open the call for questions. Operator?
現在開始接受提問。接線生?
Operator
Operator
(Operator Instructions)
(操作說明)
David Amsellem, Piper Sandler.
大衛·阿姆塞勒姆,派珀·桑德勒。
David Amsellem - Senior Research Analyst
David Amsellem - Senior Research Analyst
Hey, thanks. Just a couple here. Joe, I wanted to get your thoughts, just taking a step back on where you think penetration of LAI buprenorphine modalities ultimately could go to, or what you think would be a reasonable way to think about peak penetration of the category in the OUD space.
嘿,謝謝。我這裡只有幾個問題。喬,我想聽聽你的想法,你認為長效注射丁丙諾啡製劑的市場滲透率最終會達到什麼程度,或者你認為在阿片類藥物使用障礙(OUD)領域,該類藥物的市場滲透率峰值應該如何合理計算?
Then secondly, how we should we think about share versus your competitor? Obviously, the goal is growing volumes here, and that's been the focus, but there's a lot of, I think, investor focus on your share, even though the pie, so to speak, continues to grow. I'm wondering if you can give us some thoughts on share. That would be helpful.
其次,我們該如何看待你們與競爭對手的市佔率?顯然,我們的目標是提升銷量,這也是我們一直以來的工作重點,但我認為,投資者們非常關注你們的市場份額,儘管市場整體規模(或者說蛋糕)仍在不斷擴大。我想請您談談對市場佔有率的看法,這將對我們很有幫助。
Then lastly, you mentioned capital deployment in your prepared remarks. Wanted to get some more detailed thoughts on business development. What kind of therapeutic adjacencies or other therapeutic areas are you looking at? My assumption is that you're looking at commercial stage assets, but wanted to get more details on your thought process regarding biz devs. Thank you.
最後,您在準備好的發言稿中提到了資金部署。我想了解一些關於業務拓展的更詳細的想法。您正在關注哪些治療相關領域或其他治療領域?我假設您正在關注商業化階段的資產,但我想更詳細地了解您在業務拓展方面的想法。謝謝。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Great. Thanks, David. Look, I appreciate your questions. First off, with regards to LAI penetration, we're now embarking upon 9%, so we have to confront the reality of where we are, and we believe there is significant opportunity to continue to grow LAI penetration. We believe that long-acting injectables are underutilized. I'm not gonna get into peak penetration projections.
太好了,謝謝大衛。我很感謝你的提問。首先,關於長效注射劑的市場滲透率,我們目前已經接近9%,所以我們必須正視現實,但我們相信長效注射劑的市場滲透率還有很大的提升空間。我們認為長效注射劑的潛力尚未被充分利用。至於市場滲透率的高峰預測,我就不多說了。
However, I will share with you some analogs and data we look at that will give a sense of what is possible. If you look at categories like schizophrenia, as an example, from a long-acting injectable perspective, you would see penetration at 30%. I can assure you, we have a lot of market research here at Indivior that would support LAI penetration in the range of 20%-30%.
不過,我會分享一些我們參考的類似案例和數據,以便您了解其可能性。例如,如果您從長效注射劑的角度來看精神分裂症這類疾病,您會發現其市場滲透率可達30%。我可以向您保證,Indivior公司擁有大量的市場調查數據,這些數據支持長效注射劑的市場滲透率在20%-30%之間。
My final comment on LAI penetration is we are committed, as the long-standing leader in the space, to doing everything that we can to educate and activate consumers with regards to the important role that long-acting injectables can play. As it pertains to your question on share, what I would emphasize on share, and you're correct, our focus is really first and foremost about driving the market.
關於長效注射劑的市場滲透率,我最後想說的是,作為該領域的長期領導者,我們致力於竭盡所能,教育和引導消費者了解長效注射劑的重要作用。至於您提到的市場佔有率問題,我想強調的是,您說得對,我們首要關注的是推動市場發展。
From a share perspective, we have seen over many quarters our market share stabilizing in the mid 70%. I would emphasize that we're the only entity in the world that has perfect data on the vast majority of the market, and we've been applying a consistent methodology. Importantly, what we are most focused on is new patient share, which has been very strong, as has the absolute number of new patients.
從市佔率來看,我們已經連續多個季度將市佔率穩定在70%左右。我想強調的是,我們是全球唯一擁有絕大部分市場完整數據的機構,我們一直採用一致的分析方法。尤其重要的是,我們最關注的是新患者份額,這項指標表現非常強勁,新患者的絕對數量也是如此。
We're pretty routinely now achieving all-time highs in new patient starts. To your final question on capital deployment, look, Our start point is there are no commercial assets in the space of opioid use disorder that we believe are there that would enhance our portfolio.
我們現在幾乎每次都能創下新患者入院人數的歷史新高。至於你最後一個關於資金部署的問題,我們首先要說明的是,我們認為目前在阿片類藥物使用障礙領域沒有任何商業資產能夠增強我們的投資組合。
Once we made that determination, we'll be establishing a new strategic beachhead in a new therapeutic area. I won't say we're agnostic. There are certainly some areas we wouldn't go into, like cancer gene therapy, but what we're focused on are business fundamentals. We're looking at commercial stage only. We're looking for assets that have peak sales potential of greater than $200 million. It's important to us that the products have a long runway.
一旦我們做出決定,我們將在一個新的治療領域建立新的戰略灘頭堡。我不會說我們持中立態度。當然,有些領域我們不會涉足,例如癌症基因療法,但我們關注的是業務基本面。我們只關注商業化階段的產品。我們尋找的是最高銷售潛力超過2億美元的資產。對我們來說,產品擁有長期發展前景至關重要。
One of the strengths of the Indivior story is we have a great growth driver with a durable runway and SUBLOCADE, we wanna acquire assets that have runway that goes towards the mid to end of 2030 at a minimum. Of course, we want differentiated assets. We're not interested in being an aggregator of commoditized brands. We feel that's important from a patient value perspective, but also, when you look at it from a reimbursement perspective, we believe to get the coverage necessary to be successful commercially, that you have to have meaningfully differentiated products.
Indivior的優勢之一在於我們擁有強勁的成長動力和持久的發展前景。我們希望收購至少能持續到2030年中後期的資產。當然,我們追求的是差異化資產。我們無意成為同質化品牌的聚合商。我們認為,從病患價值的角度來看,這一點至關重要;同時,從健保報銷的角度來看,我們也相信,要獲得商業成功所需的健保覆蓋,產品必須具有顯著的差異化優勢。
David Amsellem - Senior Research Analyst
David Amsellem - Senior Research Analyst
Okay. Helpful. Thanks.
好的,很有幫助,謝謝。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Thanks, David.
謝謝你,大衛。
Operator
Operator
Chase Knickerbocker, Craig-Hallum.
蔡斯·尼克博克,克雷格-哈勒姆。
Chase Knickerbocker - Senior Research Analyst
Chase Knickerbocker - Senior Research Analyst
Good morning, guys. Congrats on the results here, thanks for taking the questions. Maybe just first digging in a little bit more to guide. Can you just kind of delineate what your guidance assumes from an LAI market growth perspective in 2026? Then, you know, to ask, I think, this question just a little bit differently on the share, what does it assume for share in 2026? Just kind of zooming in on the guide specifically, Joe. Thanks.
各位早安。恭喜你們取得這樣的成績,感謝你們回答問題。我想先深入探討一下,以便更好地理解。能否請你們從長材積水(LAI)市場成長的角度,闡述一下你們的預測假設?然後,我想換個角度問問市場份額,你們對2026年的市佔率有什麼假設?我想具體了解這份預測,Joe。謝謝。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Yeah. Chase, thanks for the question. On the SUBLOCADE guide, I'm not gonna get into an LAI penetration assumption. We're assuming mid-teen SUBLOCADE growth, which is a significant step up from where it is that SUBLOCADE was in 2025. I will comment on a market share perspective. We do expect to see continued stabilization of SUBLOCADE market share.
是的,Chase,謝謝你的提問。關於SUBLOCADE的指導方針,我不會對LAI的滲透率做出假設。我們假設SUBLOCADE的成長率為15%左右,這比SUBLOCADE在2025年的水準有了顯著提升。我會從市場佔有率的角度來談談。我們預計SUBLOCADE的市佔率將持續保持穩定。
Chase Knickerbocker - Senior Research Analyst
Chase Knickerbocker - Senior Research Analyst
Just as we wrap up 2025, you know, like you had mentioned, you guys kinda have perfect data. Can you just kinda update us on what LAI market growth was in 2025? My last question, Joe, is just a little bit more, you know, I'd appreciate some more thoughts on kind of buyback versus M&A. It's just kind of where they are on the priority list. Is this something where you'll kind of be opportunistic on M&A, and then in the meantime, you know, you guys will be, you know, fairly aggressive on the buyback as far as that being kind of the primary capital allocation after you service your debt, of course?
就在我們即將結束2025年之際,正如您之前提到的,你們掌握著非常完善的數據。能否請您簡單介紹一下2025年LAI市場的成長情況?我的最後一個問題,Joe,是關於股票回購和併購的更多細節。它們在你們的優先排序中處於什麼位置?你們是否會抓住併購機會,同時,在償還債務之後,積極進行股票回購,將其作為主要的資本配置?
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Okay, thanks, Chase. I'll let Pat take the first question and let Ryan comment on the second.
好的,謝謝,蔡斯。第一個問題就讓帕特回答,第二個問題就讓瑞恩來評論。
Patrick Barry - Chief Commercial Officer
Patrick Barry - Chief Commercial Officer
Yeah, in LAI category growth, for Q4, we were approaching 18%. Again, really strong category growth.
是的,在LAI品類成長方面,第四季我們接近18%。再次強調,這是一個非常強勁的品類成長。
Ryan Preblick - Chief Financial Officer
Ryan Preblick - Chief Financial Officer
Hey, Chase, good morning. When it comes to capital allocation, you know, due to our financial strength and the strong cash flow from the business, we have options here. It's not about or, it's about and. If you start with the debt, you know, right now we do have expensive debt, but as part of our normal cadence, it is something that we are looking at, and it is something that, you know, we will take care of in the near future. If you look at the share repurchase, this is another option we have to deliver value to our shareholders. We authorized the $400 million program to be ready to be prepared to buy back shares and be opportunistic.
嗨,Chase,早安。關於資本配置,你知道,由於我們雄厚的財務實力和強勁的業務現金流,我們有很多選擇。這不是二選一的問題,而是兩者兼顧的問題。先說說債務,你知道,我們目前的債務成本確實很高,但作為正常流程的一部分,我們正在關注這個問題,並且會在不久的將來解決它。再說股票回購,這是我們為股東創造價值的另一個選擇。我們已經批准了4億美元的回購計劃,以便隨時準備回購股票並把握機會。
That decision will be made in the context of what else is going on in the business at that point in regards to the debt conversation, BD, making sure we have the right capacity for investments behind SUBLOCADE. And then also, you know, we need to evaluate if there's still a gap between the share price and what we believe the value of the company is.
這項決定將結合當時公司其他方面的業務狀況做出,例如債務問題、業務拓展,並確保我們有足夠的資金支持SUBLOCADE的投資。此外,我們還需要評估股價與我們認為的公司價值之間是否仍存在差距。
And then finally, when it gets to the business development, you know, we're still earning our way to Phase 3, the breakout, where, as Joe Ciaffoni just said, you know, we're gonna look at BD, including buying commercial assets. Overall, we are definitely focused on driving shareholder value.
最後,在業務拓展方面,我們仍在努力邁向第三階段,也就是突破階段。正如喬·恰福尼剛才所說,我們將著眼於業務拓展,包括收購商業資產。總而言之,我們始終專注於提升股東價值。
Chase Knickerbocker - Senior Research Analyst
Chase Knickerbocker - Senior Research Analyst
Great. Thank you.
太好了,謝謝。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Thanks, Chase.
謝謝你,蔡斯。
Operator
Operator
Dennis Ding, Jefferies.
丹尼斯丁,傑富瑞集團。
Dennis Ding - Analyst
Dennis Ding - Analyst
Hi, good morning. Thanks for taking our questions. I have two. Number one, what are your thoughts on the overall Medicaid funding landscape and the potential impact on SUBLOCADE from less funding in 2027? How confident are you around maintaining that mid-teen unit growth in the US in 2027 and after? Number two, on SG&A, I'm just curious about the shape of SG&A in 2026, given it was $148 in Q4. If you can comment on how much you are spending on DTC in 2026, and, you know, at what point would you reevaluate that DTC spend in terms of growing or shrinking that? Thank you.
您好,早安。感謝您回答我們的問題。我有兩個問題。第一,您如何看待整體的醫療補助經費狀況,以及2027年經費減少可能對SUBLOCADE產生的影響?您對2027年及以後在美國維持15%左右的單位成長率有多大信心?第二,關於銷售、管理及行政費用(SG&A),鑑於第四季SG&A為1.48億美元,我很好奇2026年的SG&A情況。您能否談談2026年您在直接面向消費者(DTC)方面的支出,以及您會在什麼情況下重新評估DTC支出,考慮增加還是減少?謝謝。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Yeah. Dennis, thanks for the question. With regards to DTC, we're not going to get into how much we're spending for competitive reasons. What I will assure you is we're making every investment in support of it, and we're actually over-investing beyond what our models would suggest that we should. We're also committed to investing behind DTC at those levels for a multi-year period, because at the end of the day, the most important thing that we can do is educate and drive long-acting injectable penetration.
是的,丹尼斯,謝謝你的提問。關於直接面向消費者(DTC)業務,基於競爭原因,我們不打算透露具體的投入金額。但我可以向你保證,我們正在全力支持這項業務,而且實際上我們的投入遠超預期。我們承諾在未來幾年內繼續保持對DTC業務的投入水平,因為歸根結底,我們最重要的任務是普及長效注射劑的知識,並推動其市場滲透。
As it pertains to Medicaid, I'm not going to get into, we're just starting 2026, what we think growth would look like in 2027. What I can tell you is, one, we advocate for and are hopeful from a humanistic perspective, that everybody who should be supported by Medicaid is supported. We believe that overall, if you look at the various legislation, it's generally supportive, we view that as a bipartisan support to helping people with substance use and opioid use disorder.
關於醫療補助計畫(Medicaid),鑑於現在才剛開始2026年,我不打算深入探討我們對2027年成長率的預測。但我可以告訴大家的是,首先,從人道主義的角度來看,我們倡導並希望所有應該獲得醫療補助計劃支持的人都能得到支持。我們認為,總體而言,如果你審視一下各項立法,你會發現它們普遍支持這項計劃,我們認為這是兩黨對幫助藥物濫用和阿片類藥物使用障礙患者的支持。
The final point I would make, at 8%, 9% long-acting injectable penetration, there is so much opportunity for growth with SUBLOCADE across the board, inclusive of Medicaid. It will not be impacted whether Medicaid population is ± a certain %. I'll give Ryan the opportunity to comment on SG&A.
最後一點,鑑於長效注射劑的滲透率在 8% 到 9% 之間,SUBLOCADE 在各個領域,包括 Medicaid 人群中,都擁有巨大的成長潛力。 Medicaid 人群比例的波動不會對其產生影響。接下來,我會讓 Ryan 就銷售、管理及行政費用 (SG&A) 發表意見。
Ryan Preblick - Chief Financial Officer
Ryan Preblick - Chief Financial Officer
Yeah, good morning. In regards to the step-up in Q4, that was simply us taking advantage of our DTC campaign, tested really well, and we had the opportunity to start it early. That's the expense you're seeing in Q4. Around phasing for 2026, our quarters are relatively flat. You may see some skew to the first three quarters just due to the campaign we have in place.
是的,早安。關於第四季度的成長,那隻是因為我們充分利用了 DTC 行銷活動,該活動測試效果非常好,而且我們有機會提前啟動。這就是您在第四季度看到的支出。到 2026 年左右,我們的季度業績相對平穩。您可能會看到前三個季度的業績略有波動,這主要是由於我們正在進行的行銷活動所致。
Dennis Ding - Analyst
Dennis Ding - Analyst
Helpful. Thank you.
很有幫助,謝謝。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Thanks, Dennis.
謝謝你,丹尼斯。
Operator
Operator
Christian Glennie, Stifel.
Christian Glennie,Stifel。
Christian Glennie - Analyst
Christian Glennie - Analyst
Hi, thanks, guys. Thanks for taking the questions. First one would be on SUBLOCADE and the guide. Just so I guess to understand it properly, obviously, you had meaningful gross to net benefits. Is the idea that we, you know, adjust for that, take that off in terms of the base, the underlying, I guess, base for SUBLOCADE, that gets you, if you're doing mid-teens, that gets you to the sort of the range that you've guided to? As in, trying to, you know, compare the 8% net revenue guide versus your mid-teens guidance in dispense growth.
嗨,謝謝各位。感謝你們回答問題。第一個問題是關於SUBLOCADE和你們的指導方針。我想先確認一下,你們的毛利淨收益確實顯著。我們是不是應該把這部分收益從SUBLOCADE的基準線中扣除,這樣才能得出你們預期的15%左右的成長率?也就是說,我們想比較一下8%的淨收入成長預期和你們預期的15%左右的成長率。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Thanks for the question, Christian. look, in 2025, gross to net served as a tailwind. In 2026, gross to net will serve as a headwind to the business. The key component of the guide is the following: We're going to grow and accelerate dispense unit growth to the mid-teens, and we're assuming that we're going to continue to see a stabilization of market share.
謝謝你的提問,克里斯蒂安。你看,2025年毛利潤與淨利比對公司有利。但到了2026年,這一比例反而會成為公司的阻力。這份指南的關鍵在於:我們將推動銷售單元的成長,並加速成長至十幾個百分點,同時我們預期市場佔有率將持續保持穩定。
Christian Glennie - Analyst
Christian Glennie - Analyst
Okay, thank you. Then on the, I guess, just obviously, you know, funny enough, if we're going back to the capital markets day 2022, you talked about an exit rate to, you know, billion-dollar exit rate by the end of 2025. You've actually gone and actually done that. I guess, any observations about, you know, the potential to breach that billion-dollar number?
好的,謝謝。然後,我想,很明顯,你知道,有趣的是,如果我們回到2022年的資本市場日,你當時談到到2025年底退出率將達到10億美元。而你實際上已經實現了這個目標。我想,對於突破10億美元大關的可能性,你有什麼看法?
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
I appreciate the question. We're not going to get into any peak sales projections, any forward-looking, when we're going to hit certain thresholds. What we're focused on is delivering on the financial commitments that we made to everyone for 2026, or for 2026.
感謝您的提問。我們不會預測銷售峰值,也不會展望何時能達到某些銷售目標。我們目前的重點是兌現我們對所有人在2026年所做的財務承諾。
The final comment I would make there is we are very confident with SUBLOCADE that we have a durable growth driver, and I think we're just scratching the surface on the potential of this asset, both from a business perspective, but candidly, more importantly, in the potential it has to make a difference in a positive way in the lives of people living with opioid use disorder and the communities that we serve.
最後我想說的是,我們對 SUBLOCADE 非常有信心,認為它具有持久的成長動力。我認為,我們僅僅觸及了這項資產潛力的冰山一角,無論從商業角度來看,還是坦率地說,更重要的是,它有可能對患有阿片類藥物使用障礙的人們以及我們所服務的社區的生活產生積極的影響。
Christian Glennie - Analyst
Christian Glennie - Analyst
Thanks. My final one, if I can, maybe just to clarify a previous comment around new assets. You talked about being well-served, obviously, in OUD, in terms of it seemed to apply other therapeutic areas. Would that include other addiction therapeutic areas, or is it outside addiction?
謝謝。最後一個問題,如果可以的話,我想澄清一下之前關於新資產的評論。您提到在阿片類藥物使用障礙(OUD)領域,您顯然得到了很好的服務,而且似乎也適用於其他治療領域。這是否包括其他成癮治療領域,還是僅限於成癮領域之外?
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
I appreciate the question. First thing I want to emphasize, we're head down in Phase 2 accelerate, and we've been clear we need to earn our way to Phase 3 breakout. I would not have an expectation that anything we do from an acquisition perspective would be focused on opioid use disorder or substance use disorder.
感謝您的提問。首先我想強調的是,我們目前正全力投入第二期加速研發,我們已經明確表示,我們需要努力爭取進入第三期突破性試驗階段。從收購的角度來看,我並不認為我們的任何舉措會專注於阿片類藥物使用疾患或物質使用疾患領域。
I would think of different therapeutic areas than that, but I would bring you back to the business fundamentals that will really drive what it is that we're looking to achieve. Commercial stage, peak sales potential greater than $200 million, a long and durable runway in front of it, and a differentiated asset that would deliver both patient value and enable us to get the reimbursement we feel is necessary to be successful commercially.
我會考慮其他治療領域,但我想回到真正驅動我們實現目標的商業基本面。商業化階段,高峰銷售潛力超過2億美元,未來發展前景廣闊且可持續,以及一項差異化資產,既能為患者創造價值,又能讓我們獲得我們認為商業成功所必需的報銷。
Christian Glennie - Analyst
Christian Glennie - Analyst
Great. Thank you.
太好了,謝謝。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Welcome. Thank you.
歡迎。謝謝。
Operator
Operator
Brandon Folkes, H.C. Wainwright.
布蘭登·福克斯,H.C. 溫賴特。
Brandon Folkes - Equity Analyst
Brandon Folkes - Equity Analyst
Hi. Thanks so much for taking my call. Congrats. Maybe just a quick one for me. Can you just talk about how you think contribution from the criminal justice system opportunity in your 2026 SUBLOCADE guidance? Thank you.
您好。非常感謝您接聽我的電話。恭喜!我可能還有一個小問題。您能否談談您如何看待刑事司法系統在2026年SUBLOCADE指導方針中提出的貢獻機會?謝謝。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Yeah. Thanks, Brandon. I'm gonna give that one to Pat.
好的,謝謝你,布蘭登。我打算把這個給帕特。
Patrick Barry - Chief Commercial Officer
Patrick Barry - Chief Commercial Officer
Yeah, no, I appreciate the question, Brandon. We see the criminal justice segment as a strong opportunity for us. We see it as a rebase business. From there, we believe we can grow. Also, SUBLOCADE is a differentiated asset. It's the only monthly with a long-acting injectable monthly with the rapid induction. You have prescribers that are familiar and comfortable with it.
是的,布蘭登,我很感謝你的提問。我們認為刑事司法領域對我們來說是一個絕佳的機會,也是一個可以重新定位的業務領域。我們相信,從這個領域出發,我們可以實現成長。此外,SUBLOCADE 是一款差異化產品,它是唯一一款具有快速起效功能的長效注射型月經製劑。許多醫生都熟悉並樂於使用這款產品。
In that context, we do believe it can contribute to the growth that we're guiding to on mid-teens. Obviously, we're looking at the broader opportunity. While CJS is a part of it, we're looking at the opportunity as the category leader to continue to fuel and grow the overall LAI category.
在此背景下,我們相信它能夠助力我們實現預期的十幾歲年齡層的成長目標。顯然,我們著眼於更廣泛的機會。雖然CJS是其中的一部分,但身為品類領導者,我們更關注的是持續推動和成長整個長效注射劑(LAI)品類的潛力。
Operator
Operator
Thibault Boutherin, Morgan Stanley.
Thibault Boutherin,摩根士丹利。
Thibault Boutherin - Equity Analyst
Thibault Boutherin - Equity Analyst
Yes, thank you. Thank you for the clarification on SUBLOCADE guidance between 50% and 8%. There's also another element, it's small, but SUBLOCADE ex-US, how should we think about that line of revenues given the organization changes they've made, you've made, sorry. Should we expect this to stabilize? Could it decline next year? Just if you could help us on that.
是的,謝謝。感謝您澄清 SUBLOCADE 的績效指引在 8% 到 50% 之間。還有一點,雖然不大,但關於 SUBLOCADE 在美國以外的收入,考慮到他們(或您)所做的組織架構調整,我們應該如何看待這部分收入?我們是否應該預期它會趨於穩定?明年會不會下降?如果您能就此提供一些幫助,那就太好了。
Just on R&D, obviously, you're going to have two Phase 3 go-no-go decisions in the next few weeks. How should we think about the impact of the different scenarios on your OpEx guidance if you take zero, one, or two assets to Phase 3? Thank you.
僅就研發而言,顯然,未來幾週內您將面臨兩個三期臨床試驗的審批決定。如果您選擇零項、一項或兩項資產進入三期臨床試驗,我們應該如何看待不同方案對您的營運支出預期產生的影響?謝謝。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Sure. I'll let Ryan take the first question, and then Christian and I will split the second.
當然可以。第一個問題先讓瑞恩回答,第二個問題我和克里斯蒂安一起回答。
Ryan Preblick - Chief Financial Officer
Ryan Preblick - Chief Financial Officer
Certainly. Good morning. On SUBLOCADE and the rest of the world, it's gonna be relatively flat year-over-year. We will see growth in Australia and Canada, but we will lose some of the volume coming out of the Nordics.
當然。早安.關於SUBLOCADE以及世界其他地區,預計將比去年同期保持相對穩定。澳洲和加拿大市場將會成長,但北歐市場的交易量將會下降。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
Okay. With regards to R&D, I'll let Christian comment on the programs and timing of the Phase 2 readouts. What I would tell you is our budget for 2026 contemplates if we have the opportunity to advance those programs, that is built into the operating budget that we're working towards. Christian?
好的。關於研發方面,我會讓克里斯蒂安來談談計畫以及二期臨床試驗結果公佈的時間安排。我想告訴大家的是,我們2026年的預算已經考慮到如果我們有機會推進這些項目,這部分預算已經納入了我們正在努力實現的營運預算中。克里斯蒂安?
Christian Glennie - Analyst
Christian Glennie - Analyst
Yes. Based on what Joe just said, the two Phase 2 trials were completed at the end of the Q4 last year. We are now going through the traditional process of data cleaning, data closeout, and statistical programming. This will be followed by a database log by the end of the Q1 this year, with the final tables, figures, and listings available in the Q2 of this year for preparation of top-line results on both assets.
是的。根據喬剛才所說,兩項二期臨床試驗已於去年第四季末完成。我們目前正在進行資料清理、資料收尾和統計程式設計等常規流程。之後,我們將在今年第一季末完成資料庫日誌的整理,最終的表格、圖表和清單將於今年第二季度提供,以便我們準備兩項藥物的主要研究結果。
I must add that in addition of INDV-6001, in addition to the Phase 2 data, the decision to proceed to late-stage clinical development, that is the Phase 3, hinges on three additional factors. First, the manufacturing feasibility and the availability of the drug product for the actual Phase 3.
我必須補充一點,除了INDV-6001和第二期臨床試驗數據之外,是否進入後期臨床開發階段(即三期臨床試驗)還取決於三個其他因素。首先是生產可行性以及第三期臨床試驗所需藥物的供應。
Brandon Folkes - Equity Analyst
Brandon Folkes - Equity Analyst
Second, we are currently running a payer-validated differentiation and evidence that is going to be required for coverage based on the target product profile research. Three, the impact of that research on the clinical Phase 3 trial design, if indeed, this is what the business decides to do.
第二,我們目前正在進行一項經支付方驗證的差異化研究,該研究將是基於目標產品概況研究而得出的醫保覆蓋所需證據。第三,如果公司最終決定進行第三期臨床試驗,這項研究將對試驗設計產生何種影響。
Thibault Boutherin - Equity Analyst
Thibault Boutherin - Equity Analyst
Thank you.
謝謝。
Joe Ciaffoni - Chief Executive Officer
Joe Ciaffoni - Chief Executive Officer
You're welcome.
不客氣。
Operator
Operator
Thank you. This concludes the question and answer session and today's conference call. Thank you all for participating. You may now disconnect.
謝謝。問答環節和今天的電話會議到此結束。感謝各位的參與。現在可以掛斷電話了。